pa2

Desfesoterodine (5-HMT) is a new muscarinic receptor antagonist with Kb of 0.84 nM.

PA2-GNU7 is an antimicrobial peptide (AMP) with potent antibacterial activity, demonstrating minimum inhibitory concentrations (MIC) of 2 μM for Pseudomonas aeruginosa, 1 μM for Escherichia coli, 2 μM for Salmonella, 2 μM for Staphylococcus aureus, and 8 μM for Candida albicans. It rapidly and selectively kills Pseudomonas aeruginosa without affecting other symbiotic bacteria and significantly enhances the survival rate of mice infected with Pseudomonas aeruginosa. PA2-GNU7 has potential applications in researching and developing treatments for infections caused by multidrug-resistant Pseudomonas aeruginosa.

LPA2 antagonist 2 is a selective and potent LPA2 antagonist (IC50: 28.3 nM) with potential anticancer activity, inhibits LPA3, and can be used in the study of cancer.

LPA2 antagonist 1 is a highly efficient LPA2 antagonist.

PA21A092 is an inhibitor of PfATP4 and exhibits specific biochemical effects.

LPA2 antagonist 5 (EX1) functions as an antagonist of LPA2, with an IC50 value of 4.05 nM.

LPA2 antagonist 6 (example 2) acts as an antagonist of Lp(a). It inhibits the formation of Lp(a) with an IC50 value of 2.33 nM, making it useful for cardiovascular disease research.

gTPA2-OMe is a potential hole transport layer candidate for perovskite solar cells (PSCs).

PA22-2 (free acid) (Cys-Laminin A chain 2091-2108), a peptide, promotes neurite outgrowth and facilitates the formation of neuron-like processes. It is used in the culturing of human adenoid cystic carcinoma cells and the development of peptide-functionalized supported phospholipid bilayers [1] [2] [3].

PA22-2, an active biological peptide featuring the IKVAV sequence from the laminin A-chain fragment, is derived from mouse laminin alpha1 amino acid residues 2110-2127. Substrates composed of PA22-2 have been shown to facilitate neurite outgrowth.

PPA24 (compound 19a) is an activator of PP2A. It inhibits induced apoptosis and oxidative stress, and also reduces the expression levels of c-Myc. PPA24 is applicable in cancer research studies.

E16-uPA24 is a chimeric peptide that targets the urokinase-type plasminogen activator receptor (uPAR). It uses polyglutamic acid to modify the surface of senescent cells, promoting an immune response through glutamic acid recognition. This compound enhances immune cell recruitment and directly links senescent and immune cells, leading to the immune clearance of senescent cells and the restoration of tissue homeostasis. E16-uPA24 is applicable in research on tissue degeneration, chronic inflammatory diseases, and age-associated tumorigenesis.

Lytx-Pa2a is a peptide inhibitor that targets bacterial cell membranes (bacterialmembranes) and the TLR4 receptor (TLR4receptor). It exhibits antibacterial effects by non-competitively disrupting extracellular/cytoplasmic membranes and inhibits the LPS-induced TLR4/NF-κB signaling pathway. Lytx-Pa2a holds potential for research in bacterial infections and inflammation-related diseases, such as sepsis.

Adoprazine (SLV313) is a potential atypical antipsychotic bearing potent D2 receptor antagonist and 5-HT1A receptor agonist properties.

Tipelukast (KCA 757) is a novel, orally available leukotriene receptor antagonist with anti-inflammatory properties, capable of reducing fibrosis and down-regulating TIMP-1 and type 1 collagen. Tipelukast is utilized in asthma research.

RS 17053 hydrochloride is a potent and selective antagonist of the α1A adrenoceptor, with a pKi value of 9.1 in native cell membranes and a pA2 value of 9.8 in functional assays.

dopamine D1 receptor antagonist

Radioprotectin-1 is a selective agonist of LPA2 with EC50 of 25 nM for murine LPA2 GPCR and exerts radioprotective and radiomitigative action.

DBIBB is a non-lipid agonist of specific lysophosphatidic acid (LPA2) type 2 G-protein-coupled receptor. It is a potentially active molecule for the treatment of acute radiation syndrome caused by high intensity gamma rays on hematopoietic and gastrointestinal systems. It is an intermediate in organic synthesis and drug research. DBIBB can be used to prepare various compounds that reduce gastrointestinal radiation syndrome, increase intestinal crypt survival and intestinal cell proliferation, and reduce cell apoptosis.

6-Acryloyloxyhexyl phosphater (PA21) is a novel phosphate-binding agent, which is an iron-based reagent, and can be used for the treatment of hyperphosphatemia in chronic kidney disease.

CPX-351 (Vyxeos) is a liposomal encapsulant of cytarabine and Zoerythromycin with potential antitumor activity and can be used in the study of acute myeloid leukemia.

Aprocitentan-D4 is a deuterium-labeled Aprocitentan. Aprocitentan (T7817) is a major and pharmacologically active metabolite of Macitentan. Aprocitentan (T7817) is a dual ETA/ETB antagonist (IC50s: 3.4 nM and 987 nM; pA2s: 6.7 and 5.5).

YM158 free base is a potent and selective antagonist of the TXA2 and LTD4 receptors (pA2 values of approximately 8.81 and 8.87).

Beperidium iodide is a competitive antagonist of the acetylcholine receptor (pA2: 7.93).